ADMA Biologics (ADMA) Price & Analysis

Compare

2,973 Followers

ADMA Stock Chart & Stats

$14.72

-$0.24(-1.31%)

At close: Jan 08 4:00 PM EST

$14.72

-$0.24(-1.31%)

Day’s Range― - ―

52-Week Range$13.50 - $25.67

Previous CloseN/A

Volume407.39K

Average Volume (3M)3.26M

Market Cap

$3.49B

Enterprise ValueN/A

Total Cash (Recent Filing)$61.38M

Total Debt (Recent Filing)$83.12M

Price to Earnings (P/E)18.1

Beta0.94

Next Earnings

Mar 19, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding238,630,720

10 Day Avg. Volume3,406,507

30 Day Avg. Volume3,260,260

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)11.45

Price to Sales (P/S)9.37

P/FCF Ratio36.31

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$32.00

Price Target Upside117.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceADMA's underlying performance is strong, as evidenced by improved guidance for 2025 and 2026 following their earnings report.

Production OutputThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.

Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.

Bears Say

Regulatory FilingADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.

ADMA Biologics News

Adma Biologics reports Q3 EPS 15c, consensus 16c

Reports Q3 revenue $134.2M, consensus $130.53M. “ADMA is executing from a position of strength as we enter our...

26d ago

ADMA

Adma Biologics raises FY25 revenue view to at least $510M from at least $500M

Consensus $506.28M. Backs FY25 adjusted EBITDA view $235M. The company said, “In parallel, we continue to work towards...

26d ago

ADMA

Adma Biologics raises FY26 revenue view to at least $630M from up at least $625M

Consensus $637.85M. Raises FY26 adjusted EBITDA view to $355M from $340M. The company said, “ADMA‘s full-year 2025 and...

26d ago

ADMA

Adma Biologics options imply 14.3% move in share price post-earnings

Pre-earnings options volume in Adma Biologics (ADMA) is 9.4x normal with calls leading puts 8:3. Implied volatility suggests...

26d ago

ADMA

Adma Biologics management to meet virtually with Cantor

Virtual Meeting to be held on November 7 hosted by Cantor. Published first on TheFly – the ultimate...

28d ago

ADMA

Adma Biologics management to meet virtually with Cantor

Virtual Meeting to be held on November 10 hosted by Cantor. Published first on TheFly – the ultimate...

28d ago

ADMA

ADMA Biologics Inc. Reports Strong Q3 Earnings Call

ADMA Biologics Inc (($ADMA)) has held its Q3 earnings call. Read on for the main highlights of the...

25d ago

ADMA

ADMA Biologics Reports Strong Q3 2025 Financial Results

ADMA Biologics Inc ( ($ADMA) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

ADMA

ADMA Upcoming Earnings Report: What to Expect?

ADMA Biologics Inc (ADMA) is scheduled to report 3rd quarter earnings on 11/05/2025, after the market closes. Regarding...

29d ago

ADMA

ADMA Biologics Earnings Call Highlights Robust Growth

ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the main highlights of the...

4M ago

ADMA

ADMA Biologics Reports Strong Q2 2025 Results

ADMA Biologics Inc ( ($ADMA) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

ADMA

Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings

In the opening 90 minutes of the evening session, U.S. equity futures are up slightly – S&P 500...

4M ago

ELF

MCK

ADMA Biologics Secures $300M Credit Agreement with JPMorgan

ADMA Biologics ( ($ADMA) ) has provided an update. On August 5, 2025, ADMA Biologics entered into a...

4M ago

ADMA

Adma Biologics reports Q2 EPS 14c, consensus 14c

Reports Q2 revenue $121,98M, consensus $121.77M. The company said, “”The second quarter was another highly productive period for...

4M ago

ADMA

ADMA FAQ

What was ADMA Biologics Inc’s price range in the past 12 months?

ADMA Biologics Inc lowest stock price was $13.50 and its highest was $25.67 in the past 12 months.

What is ADMA Biologics Inc’s market cap?

ADMA Biologics Inc’s market cap is $3.49B.

When is ADMA Biologics Inc’s upcoming earnings report date?

ADMA Biologics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 107 days.

How were ADMA Biologics Inc’s earnings last quarter?

ADMA Biologics Inc released its earnings results on Nov 05, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.146 by $0.014.

Is ADMA Biologics Inc overvalued?

According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADMA Biologics Inc pay dividends?

ADMA Biologics Inc does not currently pay dividends.

What is ADMA Biologics Inc’s EPS estimate?

ADMA Biologics Inc’s EPS estimate is 0.19.

How many shares outstanding does ADMA Biologics Inc have?

ADMA Biologics Inc has 238,630,720 shares outstanding.

What happened to ADMA Biologics Inc’s price movement after its last earnings report?

ADMA Biologics Inc reported an EPS of $0.16 in its last earnings report, beating expectations of $0.146. Following the earnings report the stock price went down -8.718%.

Which hedge fund is a major shareholder of ADMA Biologics Inc?

Currently, no hedge funds are holding shares in ADMA

ADMA Biologics Stock Smart Score

Neutral

Fundamentals

Return on Equity

63.17%

Trailing 12-Months

Asset Growth

48.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADMA Biologics Inc

ADMA Biologics (ADMA) is a biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics. The company operates primarily in the healthcare sector, emphasizing the manufacture of immunoglobulins and related products that are essential for treating immune deficiencies and other serious medical conditions. ADMA's core products include Intravenous Immunoglobulin (IVIG) and subcutaneous immunoglobulin formulations, which are designed to improve the quality of life for patients with compromised immune systems.

ADMA Biologics (ADMA) Earnings & Revenues

Historic Earnings Reports

ADMA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong overall performance with record revenue growth, successful product utilization, and promising future prospects. Despite some temporary challenges in the IVIG market and a negative margin plasma sale, the company's strategic initiatives and financial outlook are positive.View all ADMA earnings summaries

ADMA Stock 12 Month Forecast

Average Price Target

$32.00

▲(117.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","22":"$22","33":"$33","16.5":"$16.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16.5,22,27.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.75076923076923,18.021538461538462,19.29230769230769,20.563076923076924,21.833846153846153,23.104615384615386,24.375384615384615,25.646153846153844,26.916923076923077,28.18769230769231,29.45846153846154,30.729230769230767,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.75076923076923,18.021538461538462,19.29230769230769,20.563076923076924,21.833846153846153,23.104615384615386,24.375384615384615,25.646153846153844,26.916923076923077,28.18769230769231,29.45846153846154,30.729230769230767,{"y":32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.75076923076923,18.021538461538462,19.29230769230769,20.563076923076924,21.833846153846153,23.104615384615386,24.375384615384615,25.646153846153844,26.916923076923077,28.18769230769231,29.45846153846154,30.729230769230767,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >